News Archive

The HiLo study seeks to determine the optimal phosphate level for patients with chronic kidney disease.

Over a third of patients with diabetes and heart disease were not taking any of the three therapies proven to prevent major adverse cardiovascular events.

The rate of transmission within schools was found to be much lower than the rate of community spread of the disease.

The study, which is the only randomized trial testing rixaroxaban in this patient population, builds on previous evidence established by the DCRI-led ROCKET-AF and ARISTOTLE studies.

Patients assigned to the treatment, omecamtiv mecarbil, experienced a statistically significant difference in a composite endpoint of time to cardiovascular death or time to first heart failure event.

By evaluating patient-reported and electronic health record data, the pragmatic clinical study adds important real-world evidence to inform clinical practice.

EDITORS' NOTE: This story was updated January 19, 2021 when the study was published in Journal of the American Medical Association.

The ISCHEMIA trial made headlines last year at the American Heart Association 2019 Scientific Sessions, where primary results were presented indicating that invasive heart procedures may not reduce

Attendees to a January 2019 DCRI Think Tank outlined recommendations for optimizing pragmatic clinical trials and weighing risks and benefits of innovative trial designs.

An analysis of a study called Mission: Lifeline STEMI Accelerator II found that when patients experiencing an ST-elevation myocardial infarction present in facilities not capable of performing percutaneous intervention, the time between their arrival and cath lab activation is an important quality metric to direct timely reperfusion.